Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

In this study, using a shampoo with Morus alba root extract over 12 weeks increased hair density and shaft thickness in patients with mild to moderate non-scarring alopecia, with both investigators and participants noting visible improvements and moderate satisfaction.

This study found that a combination of H. rosa-sinensis L. and B. racemosa extracts produced the most hair follicles in stress-induced alopecia in male Wistar albino rats.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study investigated the effectiveness of a botanical formulation, Zauberӧl®, on testosterone-induced alopecia in Wistar rats, focusing on ingredients such as Arnica montana and Hibiscus Rosa sinensis. Results are not reported in the abstract.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

This study identified ISPP-Rb, a novel immuno-stimulatory complex from Royoporus badius, that significantly activates murine macrophage cells and induces multiple proinflammatory cytokines.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study identified compounds like hexadecanoic acid, alphaspinasterol, and squalene in Cucurbita pepo roots, which may offer new pharmacological approaches for developing therapies for various conditions.

This study found that a compound isolated from Aloe barbadensis Miller showed strong effects on hair follicle regeneration and hair growth in warfarin-induced alopecia in rats, suggesting potential as a minoxidil alternative.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

This study found that the ethyl acetate extract of Fagraea berteroana fruits and its fraction FEAE-F0 promoted cell proliferation and modulated gene expression in hair follicle cells, suggesting potential for hair growth stimulation.

This source reports that clinical trials found oral baricitinib significantly improved hair regrowth in patients with severe alopecia areata, with 38.8% achieving at least 80% scalp hair coverage after 36 weeks on a 4-mg dose, compared to 6.2% with placebo in trial 1.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

Baricitinib helps with early hair regrowth in people with alopecia areata.

This study found that bufotalinin, derived from Merremia peltata leaves, may enhance hair growth by acting as a potential androgen receptor antagonist in rabbits.

This study found that rosemary extracts, both individually and in combination as shampoo and hair tonic, stimulated significant hair growth in male C57BL6//BIOU mice, even surpassing the growth achieved with the commercial drug 5% minoxidil.

This study found that certain growth media combinations influence the development of Arabidopsis thaliana root hairs, identifying specific conditions that promote the growth of the longest root hairs.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study found that fruit extracts from certain Egyptian Sabal species demonstrated significant anti-androgenic activity and potential therapeutic effects against benign prostatic hyperplasia in rat models and cell lines.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.